When was Allay Therapeutics founded?

Allay Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Allay Therapeutics located?

Allay Therapeutics is headquartered in Menlo Park, United States.

Who is the current CEO of Allay Therapeutics?

Adam Gridley of Allay Therapeutics.

How many employees does Allay Therapeutics have?

As of Aug 27, 2025, the latest employee count at Allay Therapeutics is 52.

Is Allay Therapeutics a funded company?

Allay Therapeutics is a funded company, having raised a total of $159M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2020.

When was the latest funding round of Allay Therapeutics?

Allay Therapeutics' latest funding was a $***** Venture Debt round on Jun 05, 2025, with participation from 1 investor.

Where does Allay Therapeutics rank among its competitors?

Allay Therapeutics ranks 207th amongst 2777 active competitors, of which 920 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Allay Therapeutics?

Allay Therapeutics' top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Allay Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Allay Therapeutics is a series D company based in Menlo Park (United States), founded in 2017. It operates as a Developer of drugs for post-surgical pain management. Allay Therapeutics has raised $159M in funding from investors like Arboretum Ventures, Lightstone Ventures and Clavystbio. The company has 2777 active competitors, including 920 funded and 695 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

Developer of drugs for post-surgical pain management. The company's proprietary technology platform combines non-opioid analgesics and biopolymers to create dissolvable candidates that deliver pain relief within a targeted site. The company's lead candidate is ATX-101 for post surgical knee rehabilitation. Other candidates include ATX-201 and ATX-301 injectables for on-demand delivery.

Website: www.allaytx.com/
Social
Email ID: *****@allaytx.com

Key Metrics

Founded Year

2017

Location

Menlo Park, United States

Stage

Series D

Total Funding

$159M in 6 rounds

Latest Funding Round

Venture Debt, Jun 05, 2025, $*****

Investors

Arboretum Ventures & 16 more

Ranked

207^th among 2777 active competitors

Employee Count

52 as on Aug 27, 2025

Similar Companies

Heron Therapeutics & 337 more

View Allay Therapeutics' full profile

Allay Therapeutics has raised a total funding of $159M over 6 rounds. Its first funding round was on Sep 15, 2020. Its latest funding round was a Venture Debt round on Jun 05, 2025 for $*****. 1 investor participated in its latest round. Allay Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Allay Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 05, 2025	4924474	Venture Debt	5647355	4242343	3798431	6311391
Jan 24, 2025	7601525	Series D	4762394	6410433	7140109	New Enterprise Associates & 7 more
Dec 13, 2022	9939086	Series D	7268366	5170541	4793504	Evonik

Access funding benchmarks and valuations. Sign up today!

View details of Allay Therapeutics's funding rounds and investors

Allay Therapeutics' employee count trend

Allay Therapeutics has 52 employees as of Aug 25. Here is Allay Therapeutics's employee count trend over the years:

Employee count trend for Allay Therapeutics

Uncover Allay Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Allay Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Allay Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
207th	Allay Therapeutics 2017, Menlo Park (United States), Series D	Developer of drugs for post-surgical pain management	$159M	Temasek, Vertex Growth & 15 others	57/100